Ann Crady Weiss is a prominent entrepreneur and investor known for co-founding the family planning company Modern Fertility and other ventures. Her work in fertility technology and corporate innovation has drawn significant public and investor attention.
This article outlines key financial markers, career highlights, and market impact related to Ann Crady Weiss net worth. The structured breakdown below helps readers quickly understand how her professional trajectory and business decisions shape her estimated net worth.
| Category | Key Metric | Value | Notes |
|---|---|---|---|
| Estimated Net Worth (2024) | Reported Range | $50 million to $80 million | Based on public filings, equity stakes, and reported exits |
| Primary Companies | Modern Fertility | Founder, former CEO | Co-founded with Harvard and Stanford scientists; acquired by Quest Diagnostics |
| Primary Companies | DNA Counsel | Founder | Genetic counseling platform focused on accessible hereditary cancer risk assessment |
| Major Milestones | Quest Acquisition | 2021 | Provided substantial liquidity and increased valuation multiples for early shareholders |
| Income Sources | Equity & Options | Ongoing | Vesting schedules from prior startups and ongoing equity from portfolio roles |
Modern Fertility And Market Exit Impact
Ann Crady Weiss net worth received a meaningful boost from the 2021 acquisition of Modern Fertility by Quest Diagnostics. The deal combined scientific expertise with corporate scale, creating a durable brand in at-home fertility testing. Investors and early employees, including Weiss, benefited from liquidity events tied to strategic buyer interest.
Under her leadership, Modern Fertility developed hormone testing kits and digital tools that expanded access to reproductive health insights. Strong unit economics and consistent subscription revenue improved valuation assumptions, directly influencing market-based estimates of her net worth.
DNA Counsel And New Venture Growth
Business Model And Traction
With DNA Counsel, Ann Crady Weiss targeted hereditary cancer risk through streamlined genetic counseling and testing. The model emphasized concierge-level guidance paired with insurance navigation, aiming to reduce friction for consumers and providers.
Early metrics around user acquisition and payer partnerships suggest sustainable demand. While financial specifics are private, credible third-party assessments place the venture in a growth phase that could meaningfully contribute to her net worth over time.
Professional Background And Executive Roles
Strategic Positions And Board Influence
Beyond founding roles, Ann Crady Weiss has held advisory and board positions with companies focused on reproductive health and data-driven decision tools. These roles often include equity compensation, adding long-term value to her overall net worth.
Her background at venture funds and tech-forward startups has enabled her to evaluate high-potential opportunities and allocate capital efficiently. Cross-sector experience in consumer, enterprise, and life sciences amplifies the strategic weight of her involvement.
Valuation Drivers And Market Perception
Factors Influencing Estimates
Publicly reported estimates of Ann Crady Weiss net worth rely on multiple assumptions around equity valuations, secondary transactions, and tax considerations. Documented exits from private company sales and exercised options provide a baseline, while unrealized gains remain sensitive to market conditions.
Media coverage and analyst commentary can affect perceived brand value, especially for consumer-facing health companies. Consistent execution on clinical accuracy, user trust, and regulatory compliance helps anchor long-term valuation expectations.
Key Takeaways And Recommendations
- Track equity vesting schedules and secondary transaction data for accurate wealth assessments
- Monitor new venture milestones, including product launches, insurance approvals, and user growth
- Assess market conditions in life sciences and consumer health for timing of potential liquidity events
- Diversify holdings across asset classes to manage concentration risk tied to private company equity
FAQ
Reader questions
How is Ann Crady Weiss net worth estimated given private equity holdings
Estimates combine disclosed exits, secondary sales, and valuations from recent funding rounds of companies like Modern Fertility and DNA Counsel, adjusted for taxes and dilution over time.
What role did the Quest Diagnostics acquisition play in her wealth
The acquisition provided significant liquidity through shares and cash, converting earlier risk capital into confirmed proceeds that substantially raised her net worth at the time.
Does she currently earn from board or advisory roles
Yes, serving on boards and advisory committees often includes cash fees and equity grants, both of which contribute to ongoing compensation and net worth growth.
How do new ventures like DNA Counsel affect long-term net worth projections
If DNA Counsel scales user adoption and expands payer coverage, future equity appreciation could meaningfully increase her net worth beyond current estimates.